Presenting Author:
Principal Investigator:
Department:
Radiology
Keywords:
Liver Cancer (HCC), Radiology, Liver treatment, Post resection Y90 radioembolization
Location:
Ryan Family Atrium, Robert H. Lurie Medical Research Center
C127 - Clinical
Radioembolization for Recurrent HCC Following Resection: Safety and Long-term Outcomes
Purpose: To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. Methods: With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed. Results: 41 patients met study inclusion criteria. 26 (63%) patients had undergone minor (≤3 hepatic segments) resection while 15 (37%) patients underwent major (>3 hepatic segments) resections. Two patients (5%) had biliary-enteric anastomoses created during surgical resection. The median time from HCC resection to first radioembolization was 17 months (95% CI: 13-37). The median number of Y90 treatment sessions was 1 (range: 1-5). 10 patients received whole remnant lobar treatment while 31 patients received selective (≤2 hepatic segments) treatment. Grades 1/2/3/4 bilirubin toxicity were seen in 6(14%), 4(10%), 6(14%), and 1(2.4%) patients following Y90. No differences in bilirubin toxicities were identified when comparing lobar with selective approaches (P=0.20). No post-Y90 infectious complications were identified. Median TTP was 11.3 months (CI: 6.5-15.5); median OS from Y90 was 22.1 months (CI: 10.3-31.3). Conclusion: Radioembolization is a safe and effective method to treat recurrent HCC following surgical resection, with prolonged TTP and promising survival outcomes.
